Chengdu Easton Biopharmaceuticals Co., Ltd.
SSE:688513.SS
40.64 (CNY) • At close June 6, 2025
Overview | Financials
Numbers are in millions (except for per share data and ratios) CNY.
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets: | ||||||||||||
| Current Assets: | ||||||||||||
| Cash & Cash Equivalents
| 971.405 | 781.231 | 830.967 | 1,050.695 | 1,055.289 | 404.057 | 364.78 | 272.767 | 227.036 | 71.6 | 50.248 | 28.842 |
| Short Term Investments
| 452.351 | 741.782 | 516.364 | 453.841 | 570 | 0 | 0 | 0 | 0 | 0 | 0 | 3 |
| Cash and Short Term Investments
| 1,423.756 | 1,523.013 | 1,347.33 | 1,504.536 | 1,625.289 | 404.057 | 364.78 | 272.767 | 227.036 | 71.6 | 50.248 | 31.842 |
| Net Receivables
| 288.879 | 178.364 | 180.921 | 126.727 | 151.118 | 149.496 | 104.105 | 53.754 | 51.477 | 3.535 | 5.35 | 5.766 |
| Inventory
| 190.086 | 160.981 | 140.868 | 103.683 | 84.029 | 60.413 | 51.696 | 54.93 | 42.347 | 32.264 | 28.451 | 28.677 |
| Other Current Assets
| 25.984 | 16.47 | 16.197 | 18.317 | 9.785 | 21.645 | 10.32 | 79.992 | 52.367 | 10.957 | 10.294 | 22.299 |
| Total Current Assets
| 1,928.706 | 1,882.871 | 1,709.122 | 1,779.07 | 1,893.943 | 631.294 | 528.822 | 407.689 | 321.75 | 118.356 | 94.344 | 88.583 |
| Non-Current Assets: | ||||||||||||
| Property, Plant & Equipment, Net
| 1,249.369 | 1,254.968 | 1,140.97 | 874.595 | 571.679 | 301.085 | 210.562 | 160.117 | 169.442 | 173.275 | 170.306 | 127.348 |
| Goodwill
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1.23 | 1.446 | 1.446 |
| Intangible Assets
| 109.366 | 84.456 | 77.008 | 41.757 | 34.219 | 35.227 | 36.047 | 14.772 | 14.348 | 14.17 | 14.447 | 14.879 |
| Goodwill and Intangible Assets
| 109.366 | 84.456 | 77.008 | 41.757 | 34.219 | 35.227 | 36.047 | 14.772 | 14.348 | 15.4 | 15.893 | 16.325 |
| Long Term Investments
| -371.64 | -660.701 | -469.707 | 4.298 | 3.418 | 4.112 | 0.521 | 0.072 | 0.151 | 0 | 0 | 0 |
| Tax Assets
| 11.504 | 8.57 | 8.731 | 12.157 | 8.727 | 3.413 | 3.935 | 4.469 | 2.932 | 0 | 0 | 0 |
| Other Non-Current Assets
| 472.823 | 776.59 | 551.415 | 63.391 | 18.871 | 11.95 | 9.808 | 4.858 | 11.594 | 4.593 | 2.557 | 22.606 |
| Total Non-Current Assets
| 1,471.422 | 1,463.883 | 1,308.418 | 996.197 | 636.914 | 355.788 | 260.872 | 184.29 | 198.467 | 193.269 | 188.755 | 166.279 |
| Total Assets
| 3,400.128 | 3,346.754 | 3,017.54 | 2,775.266 | 2,530.857 | 987.081 | 789.694 | 591.979 | 520.217 | 311.625 | 283.099 | 254.862 |
| Liabilities & Equity: | ||||||||||||
| Current Liabilities: | ||||||||||||
| Account Payables
| 144.347 | 135.137 | 156.859 | 203.916 | 122.732 | 51.175 | 31.837 | 9.704 | 14.157 | 18.148 | 32.074 | 20.223 |
| Short Term Debt
| 74.438 | 180.948 | 105.293 | 20.023 | 40.028 | 4.695 | 0 | 0 | 0 | 3.572 | 24.182 | 40 |
| Tax Payables
| 24.124 | 15.867 | 14.711 | 16.77 | 17.71 | 14.771 | 14.357 | 10.155 | 9.246 | 0 | 0 | 0 |
| Deferred Revenue
| 0 | 31.982 | 28.71 | 203.169 | 219.226 | 199.693 | 19.576 | 44.311 | 0 | 0 | 0 | 0 |
| Other Current Liabilities
| 353.41 | 297.16 | 252.525 | 180.757 | 188.336 | 188.886 | 146.579 | 110.355 | 87.87 | 21.696 | 23.592 | 26.021 |
| Total Current Liabilities
| 596.319 | 661.094 | 529.387 | 432.459 | 385.275 | 277.116 | 192.773 | 130.214 | 111.273 | 43.415 | 79.847 | 86.243 |
| Non-Current Liabilities: | ||||||||||||
| Long Term Debt
| 35.933 | 39.6 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue Non-Current
| 68.249 | 41.183 | 42.811 | 51.028 | 50.335 | 12.521 | 14.728 | 16.485 | 19.154 | 0 | 0 | 0 |
| Deferred Tax Liabilities Non-Current
| 1.705 | 1.457 | 0.883 | 0.115 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Non-Current Liabilities
| 105.887 | 82.24 | 43.693 | 51.143 | 50.335 | 12.521 | 14.728 | 16.485 | 19.154 | 0 | 0 | 0 |
| Total Liabilities
| 702.206 | 743.334 | 573.081 | 483.602 | 435.61 | 289.638 | 207.501 | 146.699 | 130.427 | 43.415 | 79.847 | 86.243 |
| Equity: | ||||||||||||
| Preferred Stock
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Common Stock
| 176.532 | 120.09 | 120.09 | 120.09 | 120.09 | 90 | 90 | 90 | 90 | 86.5 | 82.5 | 82.5 |
| Retained Earnings
| 1,128.748 | 979.583 | 820.259 | 667.409 | 485.651 | 323.848 | 247.739 | 120.337 | 84.713 | 22.049 | 77.368 | 48.136 |
| Accumulated Other Comprehensive Income/Loss
| 0 | 61.291 | 60.062 | 60.117 | 45.457 | 61.208 | 244.454 | 234.943 | 0 | 1.991 | 1.071 | 0.408 |
| Other Total Stockholders Equity
| 1,392.642 | 1,442.456 | 1,504.111 | 1,504.166 | 1,489.506 | 283.596 | 244.454 | 234.943 | 215.077 | 133.793 | 26.4 | 26.4 |
| Total Shareholders Equity
| 2,697.922 | 2,603.42 | 2,444.46 | 2,291.665 | 2,095.247 | 697.444 | 582.193 | 445.28 | 389.79 | 244.332 | 187.34 | 157.443 |
| Total Equity
| 2,697.922 | 2,603.42 | 2,444.46 | 2,291.665 | 2,095.247 | 697.444 | 582.193 | 445.28 | 389.79 | 244.332 | 187.34 | 157.443 |
| Total Liabilities & Shareholders Equity
| 3,400.128 | 3,346.754 | 3,017.54 | 2,775.266 | 2,530.857 | 987.081 | 789.694 | 591.979 | 520.217 | 287.747 | 267.187 | 243.687 |